Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0V2QU
|
||||
Former ID |
DNCL002074
|
||||
Drug Name |
Anti-CD22/CD19 mab-toxin conjugate
|
||||
Drug Type |
Monoclonal antibody
|
||||
Indication | Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10:C91.0] | Investigative | [525761] | ||
Company |
Abiogen Pharma
|
||||
Target and Pathway | |||||
Target(s) | B-lymphocyte antigen CD19 | Target Info | Modulator | [525761] | |
B-cell receptor CD22 | Target Info | Modulator | [525761] | ||
NetPath Pathway | IL-7 Signaling Pathway | ||||
PANTHER Pathway | B cell activationP00010:B cell activation | ||||
Pathway Interaction Database | BCR signaling pathwaybcr_5pathway:BCR signaling pathway | ||||
Reactome | PIP3 activates AKT signaling | ||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
Constitutive Signaling by Aberrant PI3K in Cancer | |||||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengersR-HSA-198933:Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.